Use of rivastigmine

ADMED_ACHEI_RIVASTIGMINE

No definition available.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC N06DA03

2880

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

2373

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

2373

diagram downward connector

Include endpoints None

2373

diagram downward connector
ADMED_ACHEI_RIVASTIGMINE

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 2296 1072 1224
Unadjusted prevalence (%) 0.74 0.62 0.91
Mean age at first event (years) 77.84 78.61 77.16

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: ADMED_ACHEI_RIVASTIGMINE – Use of rivastigmine
GWS hits:

Survival analyses between endpoints

Plot

before Use of rivastigmine
after Use of rivastigmine

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Use of rivastigmine